ARA. A. Roest

A. A. Roest

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


A. A. Roest has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fetal echocardiography of a Vegf overexpression model shows impaired sino-atrial nodal function consistent with abnormal morphology

    by E. E. Calkoen, N. H. Hahurij, R. Vicente-Steijn, C. Munsteren Van, A. C. Gittenberger-De Groot, M. J. Schalij, P. Steendijk, N. A. Blom, A. A. Roest, M. R. M. Jongbloed

    • 16 February 2008
      • Vol. 152  (7) , 389-92

    [Treatment of foetal supraventricular tachycardia with antiarrhythmic medication administered through the umbilical vein].

    by A A W Roest, F P H A Vandenbussche, F J C M Klumper, D Oepkes, M E B Rijlaarsdam, N A Blom

    Foetal supraventricular tachycardia (SVT) with hydrops foetalis is associated with a high morbidity and mortality rate. If SVT with hydrops foetalis persists despite transplacental therapy, direct foetal treatment can be initiated. One foetus was found to have SVT with hydrops foetalis during the 29th week of pregnancy, and the condition persisted despite transplacental treatment. Amiodarone was administered directly via the umbilical vein, and the SVT resolved. A second foetus was found to have SVT with hydrops foetalis during the 28th week of pregnancy. The condition persisted despite maternal antiarrhythmic medication. Direct treatment of the foetus with amiodarone was successful. Amiodarone is the treatment of choice for direct foetal therapy for SVT, and can be administered safely via the umbilical vein. Direct foetal therapy should be considered for the treatment of foetal SVT with hydrops foetalis that occurs in the first 31 weeks of pregnancy and persists despite adequate transplacental therapy.

    • 4 December 2004
      • Vol. 148  (49) , 2451-6

    [Tachypnoea and dyspnoea in two infants due to dilated cardiomyopathy associated with an anomalous origin of the left coronary artery].

    by A A Roest, L H Filippini, R A Van Unnik-Treurniet, N A Blom

    Two infants were referred to the emergency ward: a 3.5-month-old male infant in whom sweating and shortness of breath were seen during drinking and crying, and a 5-week-old girl that had drunk less the past day, moaned while breathing for the past few hours and had become increasingly drowsy. They were not suffering from an infection but from a dilated cardiomyopathy based on an anomalous origin of the left coronary artery from the pulmonary artery. The left coronary artery was then implanted in the aorta surgically. Both patients recovered well. Airway tract infection and sepsis are obvious common differential diagnostic considerations when confronted with a tachy-dyspnoeic infant. However, a cardiac cause, such as a dilated cardiomyopathy with cardiac decompensation, must also be considered as the presentation can be similar. The abnormal origin of the left coronary artery from the pulmonary artery is one of the few readily well treatable causes.